CatalYm GmbH
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.catalym.com
Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Visugromab in Cachexia International Trial
- Conditions
- Cancer-associated Cachexia
- Interventions
- Drug: Visugromab (CTL-002)Drug: Placebo
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- CatalYm GmbH
- Target Recruit Count
- 518
- Registration Number
- NCT07112196
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor
- Interventions
- Drug: Matching placebo for visugromab
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- CatalYm GmbH
- Target Recruit Count
- 107
- Registration Number
- NCT07098988
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer
- Conditions
- Muscle invasive bladder cancer set to undergo radical cystectomy who cannot receive or refuse to receive cisplatin-based chemotherapy
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- CatalYm GmbH
- Target Recruit Count
- 31
- Registration Number
- 2024-513957-55-00
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University, Milan, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica, Roma, Italy
First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)
- Conditions
- Solid Tumor, Adult
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- CatalYm GmbH
- Target Recruit Count
- 274
- Registration Number
- NCT04725474
- Locations
- 🇩🇪
Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik, Essen, Germany
🇩🇪Universitätsklinikum Frankfurt, Medizinische Klinik I, Frankfurt am Main, Germany
🇩🇪Universitätsklinikum Würzburg, Comprehensive Cancer Center, Würzburg, Germany
News
CatalYm Initiates Phase 2b Trial of Visugromab in First-Line Metastatic NSCLC
CatalYm has dosed the first patient in a randomized Phase 2b trial evaluating visugromab combined with chemoimmunotherapy as first-line treatment for metastatic non-squamous NSCLC.
CatalYm Strengthens Leadership Team to Advance Visugromab Through Late-Stage Development
CatalYm appointed four experienced executives to accelerate visugromab's progression into late-stage clinical development following promising Phase 2a results.
CatalYm's Visugromab Shows Promise in Enhancing Antibody-Drug Conjugate Efficacy by Blocking GDF-15
New preclinical data reveals that visugromab, CatalYm's GDF-15-neutralizing antibody, significantly enhances the anti-tumor activity of antibody-drug conjugates (ADCs) in multiple solid tumor models.